Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)

Main Inclusion Criteria: * Female outpatients aged 18-65 years (both inclusive). * Patients suffering of symptoms of uncomplicated lower urinary infection at screening. Patients must have a total sum score of at least six for the symptoms dysuria, frequency and urgency. * Development of symptoms within a maximum of 6 days before screening. * Willing to refrain from consuming prohibited concomitant medications and products. * Non-lactating female patients, who are surgically sterile (have had a documented bilateral oophorectomy and/or hysterectomy) or postmenopausal (cessation of menses for more than 1 year), or patients of childbearing potential with a negative pregnancy test at screening willing to use effective contraception methods (intrauterine device \[IUD\], hormonal contraceptives) during the study. Main Exclusion Criteria: * Any signs evoking complicated UTI, pyelonephritis and/or concomitant vulvo-vaginitis * Any conditions that may lead to complicated infections (that is, renal diseases, urinary tract abnormalities or past urinary surgery, urine catheterization, etc). * Chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound or cystoscopy. * Current signs or symptoms of severe, progressive or uncontrolled life-threatening systemic disease i.e. renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease. * Other acute infection (except UTI) requiring antibiotic treatment. * Patients receiving treatment for presumed or proven urinary tract infection within 4 weeks prior to study entry. * Antibiotic, immunosuppressive or immunostimulant (incl. vaccines) therapy within 4 weeks prior to study entry. * Patients with known history of anatomical genitourinary (GU) anomalies or GU surgery within 6 months prior to study entry. * Patients with known clinically significant abnormalities in screening physical examination, laboratory tests or vital signs. * Peptic ulcers and hypersensitivity and/or idiosyncrasy to centaury herb, lovage root, rosemary leaves or one of the other ingredients of the investigational medicinal product. * Rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, galactose intolerance or lactase deficiency. * Patients with a history of severe drug allergy or hypersensitivity. * Known Human Immunodeficiency Virus (HIV)-seropositivity.